Rare Fat-Loss disorder drug under safety review

NCT ID NCT04026178

Completed Disease control Sponsor: Aegerion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 24 times

Summary

This study looked at how the body reacts to metreleptin, a daily injection for generalized lipodystrophy, a rare condition where people lose body fat. Researchers checked for antibodies that might affect the drug's safety or effectiveness. The study involved 11 patients and was done after the drug was already approved to ensure long-term safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Endocrinology Research Associates

Columbus, Ohio, 43201, United States
Ochsner Clinic

New Orleans, Louisiana, 70121, United States
Ohio State University

Columbus, Ohio, 43203, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
Univ. Alabama-Birmingham

Birmingham, Alabama, 35294, United States
University Texas Southwestern INT

Dallas, Texas, 75390, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

GENERALIZED LIPODYSTROPHY